سعر Milnavella 50 mg 30 f.c. tabs. 2025

Milnacipran hydrochloride 50 mg film-coated tablets, pack of 30 (Milnavella, Mash Premiere).

• Management of fibromyalgia in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of major depressive episodes in adults.Population: AdultsBase de Données Publique des Médicaments (ANSM, France)

• Most frequent adverse reactions (5% or more and at least twice placebo) in fibromyalgia trials: constipation, hot flush, hyperhidrosis, vomiting, palpitations, increased heart rate, dry mouth and hypertension; nausea was the most common reason for withdrawal.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Contraindicated with MAO inhibitors intended to treat psychiatric disorders (or within 5 days of stopping milnacipran, or within 14 days of stopping an MAOI); do not start in patients treated with linezolid or intravenous methylene blue.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Contraindicated with irreversible non-selective MAO inhibitors, selective MAO-B inhibitors, digitalis glycosides and 5-HT1D agonists (triptans); during breastfeeding; in uncontrolled hypertension and severe or unstable coronary disease; hypersensitivity. Generally not recommended with parenteral adrenaline/noradrenaline, clonidine and related drugs, selective MAO-A inhibitors, and in prostatic hypertrophy or other genitourinary disorders.General active-ingredient information · Base de Données Publique des Médicaments (ANSM, France)

• Boxed warning: antidepressants increase the risk of suicidal thoughts and behaviours in children, adolescents and young adults; monitor for clinical worsening and emergence of suicidal thoughts.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serotonin syndrome (risk increased with triptans, tricyclics, fentanyl, tramadol, lithium, St John's wort and other serotonergic drugs); increased blood pressure and heart rate; seizures; hepatotoxicity; discontinuation syndrome; hyponatraemia; abnormal bleeding (with NSAIDs, aspirin, anticoagulants); activation of mania; dysuria/urinary hesitancy; angle-closure glaucoma; avoid substantial alcohol use.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MAO inhibitors (including linezolid and intravenous methylene blue)Increased risk of serotonin syndrome; concomitant use is contraindicated (allow 14 days after an MAOI and 5 days after milnacipran).DailyMed (U.S. National Library of Medicine)
• Serotonergic drugs (triptans, tricyclics, fentanyl, tramadol, lithium, tryptophan, buspirone, St John's wort)Increased risk of serotonin syndrome; monitor if used together.DailyMed (U.S. National Library of Medicine)
• NSAIDs, aspirin, warfarin and other drugs affecting coagulationIncreased bleeding risk with SNRIs.DailyMed (U.S. National Library of Medicine)

• Data in pregnancy are insufficient to evaluate drug-associated risk; SNRI exposure in the month before delivery is associated with a less than 2-fold increase in postpartum haemorrhage. Neonates exposed late in the third trimester have developed complications requiring prolonged hospitalisation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Pregnancy: data are insufficient; as a precaution, avoid use during pregnancy.General active-ingredient information · Base de Données Publique des Médicaments (ANSM, France)
• Milnacipran is present in human milk; weigh benefits of breastfeeding against the mother's need; monitor exposed infants for agitation, irritability, poor feeding and poor weight gain.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Milnacipran hydrochloride: Inhibits neuronal reuptake of norepinephrine and serotonin (about 3-fold more potent for norepinephrine in vitro) without direct effect on dopamine uptake; its mechanism in fibromyalgia is unknown.